摘要
目的： 评价含泰素的联合化疗方案治疗晚期非小细胞肺癌的疗效及不良反应。方法： 对３０ 例晚期非小细胞肺癌患者采用含泰素联合化疗， 每例至少化疗２ 周期。结果： 完全缓解２ 例， 部分缓解１１ 例， 总有效率４４ ％ ， 中位缓解期６ 个月，中位生存期１０ 个月， １ ～２ 年生存率分别为４０ ％ ， １７ ％ 。主要不良反应： 骨髓抑制、恶心呕吐、脱发， 多为Ⅱ°～Ⅲ°。结论： 含泰素的联合化疗方案对晚期非小细胞肺癌有明显疗效， 不良反应能耐受， 临床上应注意及预防其超敏反应。
Objective:To study the curative effects and toxicities of Paclitaxel combined chemotherapy.Method:30 patients with advanced non small cell lung cancer (NSCLC)were treated by Paclitaxel combined chemotherapy,which at least each of given 2 cycles.Result:The total effective rate was 44%,with CR 2 cases, PR 11s.The mid remission and survival stages were 6 months and 10 months,respectively.The survival rates of a year and 2 years were 40%,17%,respectively.The main reactions of toxicity were grade Ⅱ°～Ⅲ° myelosuppression,vomiting,alopecia.Conclusion:Paclitaxel combined chemotherapy is an effective and safe method in treating advanced NSCLC.
出处
《汕头大学医学院学报》
1999年第2期35-35,39,共2页
Journal of Shantou University Medical College
关键词
泰素
非小细胞肺癌
联合化疗
疗效
Paclitaxel,Non small Cell Lung Cancer,Combination Chemotherapy
